TUESDAY, OCTOBER 29, 2024 Third Quarter 2024 Financial Results Nasdaq: EXEL EXELIXIS® Today's Agenda Introduction Varant Shirvanian Director, Investor Relations Business Update and Q3 2024 Highlights Michael M. Morrissey, Ph.D. President and CEO Financial Results & Guidance Chris Senner EVP and CFO Commercial Update PJ Haley EVP, Commercial Q&A All, joined by: Amy Peterson, M.D. EVP, Product Development and Medical Affairs and CMO Dana T. Aftab, Ph.D. EVP, Discovery and Translational Research and CSO 2 Safe ...